Alison Hanstead represents clients in complex patent and antitrust litigations and commercial disputes, in both federal and state courts.
She has significant experience with Hatch-Waxman-related litigation, and advises clients on the intellectual property and regulatory aspects of transactional matters in the pharmaceutical industry. Clients also benefit from her experience conducting due diligence investigations and drafting license agreements.
Counsel to Boehringer Ingelheim in In re Aggrenox Antitrust Litigation MDL (D. Conn.) concerning antitrust challenge to a patent settlement agreement.
Counsel to Javelin and Hospira in a patent infringement case pending in the District of Delaware against Mylan concerning patents that cover Dyloject®, a nonsteroidal anti-inflammatory drug for intravenous administration.
Counsel to Pfizer in a series of patent infringement cases against multiple defendants concerning patents that cover Detrol LA®, a long-acting version of Pfizer's market-leading drug for overactive bladder. Won claim construction hearing on all disputed terms and the cases then settled on favorable terms for Pfizer.
Counsel to Pfizer in its five-year patent infringement case against Teva and IVAX concerning patent that covers Detrol®. After a five-day bench trial, the District Court for the District of New Jersey issued an opinion rejecting all defendants' challenges to the validity of Pfizer's patent.
Represented a major pharmaceutical company in an arbitration concerning whether the client's product was covered by another major pharmaceutical company's patent. One day after the arbitration hearing, the three-member panel ruled for White & Case's client on all issues, including determining that there was no infringement of any claim and awarding the adverse party no damages.
Trial counsel to an entertainment technology company in a breach of contract dispute.
Counsel to Warner Chilcott and Watson in In re Loestrin Antitrust Litigation (D. R.I.) concerning antitrust challenges to patent settlement agreements, as well as claims of fraud on the PTO and so-called "product hopping." After an initial motion to dismiss victory, the First Circuit Court of Appeals recently remanded the case for the district court to consider additional bases for dismissal.
Counsel to Warner Chilcott and Allergan in In re Asacol Antitrust Litigation (D. Mass.) concerning antitrust challenge to patent settlement agreement and so-called "product hopping."
Advised brand pharmaceutical clients on parameters for proposed patent settlement agreements and negotiation of same.